Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Trial Profile

Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs REP 2139-Ca (Primary) ; Entecavir; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors REPLICor
  • Most Recent Events

    • 06 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2016 According to a Replicor media release, updated clinical data of this study will be presented at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver.
    • 10 Apr 2015 According to a REPLICor media release, the updated data from this and another trial will be presented at the 2015 Lancet Viral Hepatitis Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top